Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daraxonrasib versus docetaxel in previously treated RAS-mutated non-small cell lung cancer
NL-OMON60514Phase 3Active, not recruiting
- Sponsor
- Revolution Medicines
- Start
- Sep 2025
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of daraxonrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Revolution Medicines. Primary endpoints: Progression-free survival and Overall survival. Started Sep 2025; status: active, not recruiting.
02
Drugs
daraxonrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60514.